Pfizer announces U.S. FDA filing acceptance of supplemental new drug application for XELJANZ® (tofacitinib citrate) for the treatment of adult patients with active psoriatic arthritis

5th May 2017 Uncategorised 0

Pfizer

More: Pfizer announces U.S. FDA filing acceptance of supplemental new drug application for XELJANZ® (tofacitinib citrate) for the treatment of adult patients with active psoriatic arthritis
Source: MDlinx